MedTrace Logo

Impact of Computerized Reminders on Blood Pressure Documentation and Control

NCT01640704 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2012-07-16

No results posted yet for this study

Summary

Numerous studies have examined potential causes for the racial differences in HTN prevalence and severity including baseline insulin levels, sympathetic nervous activity, intracellular calcium levels and intracellular sodium levels.\[21-23\] However, to our knowledge, there have been no studies examining the relationship of physician adherence to JNC guidelines to racial disparities in outcomes from HTN; nor have there been published studies examining the use of interventions such as computerized decision support tools or case-management to improve JNC adherence with the goal of reducing racial differences in blood pressure control. The aims of this study are: 1) To determine if physician's prescribing practices for HTN medications adhere to JNC guidelines for drug therapy.

2\) To determine if there are variations in adherence to JNC guidelines based on patient race.

3\) To determine if adherence to JNC guidelines improves blood pressure control. 4) To determine if the use of computerized medical reminders improves adherence to JNC guidelines.

Conditions

Interventions

BEHAVIORAL

Computerized reminders about treatment guidelines to providers who care for hypertensive patients

Sponsors & Collaborators

  • Agency for Healthcare Research and Quality (AHRQ)

    lead FED

Principal Investigators

  • LeRoi S. Hicks, MD, MPH · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2005-02-28
Completion
2005-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01640704 on ClinicalTrials.gov